Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGX-4010 for Painful HIV-Associated Neuropathy
NCT00085761Phase 3Terminated
- Sponsor
- NeurogesX
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of capsaicin 8% patch in HIV-associated neuropathy (2 arms), sponsored by NeurogesX. Primary endpoint: Numeric Pain Rating Scale at 12 weeks. Status: terminated.
02
Drugs
capsaicin 8% patch
03
Conditions
HIV-associated neuropathy
Beyond the preview
Go deeper on NCT00085761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085761.